No­var­tis broad­ens BRAF/MEK can­cer com­bo use, win­ning tu­mor-ag­nos­tic ap­proval in pa­tients 6 and up

No­var­tis nabbed an­oth­er FDA win for its Tafin­lar and Mekin­ist can­cer com­bo, this time broad­en­ing its la­bel quite wide­ly.

US reg­u­la­tors green­light­ed the ther­a­py for any sol­id tu­mor in pa­tients with BRAF V600E mu­ta­tions whose can­cers are un­re­sectable or metasta­t­ic. In­di­vid­u­als as young as 6 will be el­i­gi­ble to take the drug, mak­ing it the first BRAF/MEK in­hibitor ap­proved in pe­di­atrics, No­var­tis said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER